Clinical trial
RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer
NCT00409292 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00409292 |
|---|---|
| Title | RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer |
| Official title | Phase II Study of RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Massachusetts General Hospital Beth Israel Deaconess Medical Center Novartis Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | RAD001 |
| Enrollment | 33 |
| Start date | Jan 1, 2007 |
| Primary completion | Jan 1, 2009 |
| Completion | May 1, 2009 |
| First posted | Dec 8, 2006 |
| Last update posted | Aug 11, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: